Results 81 to 90 of about 48,636 (310)
Frontiers in ImmunologyCD19-directed CAR T-cell therapy is a breakthrough immunotherapy for B-cell malignancies. However, CD19 loss-mediated relapsed/refractory disease continues to pose a significant challenge, highlighting the urgent need for CAR T cells targeting ...
Yuejiao Huang +7 more
doaj +1 more source
Advanced Science, EarlyView.Colorectal cancer is characterized by an immunosuppressive microenvironment that limits immunotherapy efficacy. We identify a senescence‐like state in germinal center B cells driven by the PRELID1–VDAC3 axis, which promotes IL‐7 secretion, alleviates CD8+ T‐cell exhaustion, and enhances antitumor immunity. Targeting this pathway improves responsiveness
Yuhan Liao +8 more
wiley +1 more source
Selection of an Anti-CD20, Single-Chain Antibody by Phage ELISA on Fixed Cells
BioTechniques, 1999 Cloning the correct genes that code for antibody-variable domains from hybridomas is often complicated by the presence of several immunoglobulin transcripts, some of them arising from a myeloma cell line.
Stefanie Schmidt +3 more
doaj +1 more source
Advanced Science, EarlyView.ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley +1 more source
B-cell depletion therapy for multiple sclerosis
Immunological Medicine, 2021 Since the initial observation of increased immunoglobulin concentrations in the cerebrospinal fluid of multiple sclerosis (MS) patients in the 1940s, B cells have been considered to participate in the pathology of MS through the production of ...
Yusei Miyazaki, Masaaki Niino
doaj +1 more source
Immunoscintigraphy for therapy decision making and follow-up of biological therapies [PDF]
, 2016 With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets.
Auletta, S. +6 more
core +2 more sources
Annals of Gastroenterological Surgery, EarlyView.In advanced colorectal cancer, tumors with mature tertiary lymphoid structures (TLS) exhibited abundant infiltration of CD3‐ and CD8‐positive lymphocytes in both primary and metastatic sites, indicating an activated immune response. The presence of mature TLS was also associated with favorable chemotherapy sensitivity and improved prognosis.
Nobuhiro Hosoi +9 more
wiley +1 more source
American Journal of Hematology, EarlyView.ABSTRACT Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed.
Nancy L. Bartlett +20 more
wiley +1 more source
HHV8-Negative Primary Effusion Lymphoma of B-Cell Lineage: Two Cases and a Comprehensive Review of the Literature [PDF]
, 2013 Primary effusion lymphoma (PEL) is a rare extranodal lymphoma that typically presents in a body cavity in the absence of a detectable tumor mass and that occurs predominantly in immunosuppressed individuals.
Grohs, Heinz K. +5 more
core +3 more sources
Advanced NanoBiomed Research, EarlyView.This review explains how biomaterials and nanoparticles can be used to induce or modulate tertiary lymphoid structures (TLSs), which are ectopic immune hubs that form in nonlymphoid tissues during chronic disease and cancer. By comparing different methods, the article highlights design principles for modeling TLSs or recapitulating specific TLS ...
Shaza Karaman, Mei ElGindi, Jeremy Teo
wiley +1 more source